glp-1 receptor pathway PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: GLP-1-based therapies for type 2

RM-131 (100 g/day, subcutaneous) accelerated gastric emptying in patients with type 1 or 2 diabetes who had upper gastrointestinal symptoms

doi: 10.1056/NEJMp2400978 Summary Keywords GIP, GLP-1, GLP-1RA, tirzepatide, diabetes, obesity, cardiovascular disease Citation Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Results: From randomization to year 1, liraglutide 3.0 mg recipients lost 5.8 kg (95% confidence interval 3.78.0) more weight than those on placebo and 3.8 kg (1.66.0) more than those on orlistat ( P 0.0001

Diabetes Res Clin Pract.1994 Aug;25(1):43-9

Factors such as baseline weight, metabolic health, dietary habits, and adherence to the trial protocol all influence outcomes

Subscribe to MO HealthNet News to ensure you receive this information